Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy and safety of oral minocycline in patients who have experienced an acute spontaneous intracerebral hemorrhage within 48 hours of onset. This prospective, multicenter, randomized, double-blind, placebo-controlled Phase III trial aims to improve patient outcomes and explore the effects of minocycline on venous neuroinflammation in this condition. Participants will be randomly assigned to receive either minocycline or a matching placebo for 5 days alongside standard medical care. The minocycline group will take an initial dose of 200 mg immediately after randomization, followed by 100 mg every 12 hours for a total of 10 doses. Those with swallowing difficulties may receive the medication through a nasal feeding tube. The trial includes screening, treatment, and follow-up phases with visits scheduled at screening, 72 hours, 7 days, 90 days, and 180 days after randomization. During the study, participants will undergo assessments including neurological evaluations and imaging at specified time points. Researchers will measure outcomes such as the modified Rankin Scale score at 90 days, changes in neurological scores, inflammation markers, and stroke recurrence. Safety and efficacy will be monitored through these evaluations, with total participation lasting up to 180 days post-randomization.
Actively Recruiting
Researchers are evaluating the effect, safety, and cost-effectiveness of low-sodium salt substitutes in reducing blood pressure and preventing hypertensive disorders in pregnant women at high risk in China. This study will enroll about 3,200 pregnant women at or before 16 weeks of gestation from multiple hospitals across several provinces. The trial uses an adaptive two-phase design, with an interim analysis after the first 400 participants to decide on continuation and sample size adjustments. Participants will be randomly assigned in equal groups to either use a potassium-enriched salt substitute containing 25% potassium chloride and 75% sodium chloride or continue using usual salt with over 99% sodium chloride. The assigned salt will be provided free of charge and used for home-prepared meals until delivery. Follow-up will continue through all antenatal visits and delivery to collect blood pressure data and monitor the incidence of hypertensive disorders and related adverse events. Participants will attend regular antenatal check-ups where blood pressure and other health data will be collected. The primary outcomes include the change in systolic blood pressure from baseline to about 36-37 weeks gestation and the incidence of new hypertensive disorders and maternal adverse events from randomization to delivery. Researchers will also assess safety, adherence, and cost-effectiveness during the study, which continues until delivery for each participant.